Abstract:T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating lymphocytes is a predictor of favorable patient prognosis for many indications and is a requirement for responsiveness to immune checkpoint blockade therapy targeting programmed cell death 1. For tumors lacking immune infiltrate, or for which antigen processing and/or presentation has been downregulated, a promising immunotherapeutic approach is chimeric antigen receptor (CAR) T-cell therapy. CARs are hybrid receptors that link the tumor antigen specificity and affinity of an antibody-derived single-chain variable fragment with signaling endodomains associated with T-cell activation. CAR therapy targeting CD19 has yielded extraordinary clinical responses against some hematological tumors. Solid tumors, however, remain an important challenge to CAR T-cells due to issues of homing, tumor vasculature and stromal barriers, and a range of obstacles in the tumor bed. Protumoral immune infiltrate including T regulatory cells and myeloid-derived suppressor cells have been well characterized for their ability to upregulate inhibitory receptors and molecules that hinder effector T-cells. A critical role for metabolic barriers in the tumor microenvironment (TME) is emerging. High glucose consumption and competition for key amino acids by tumor cells can leave T-cells with insufficient energy and biosynthetic precursors to support activities such as cytokine secretion and lead to a phenotypic state of anergy or exhaustion. CAR T-cell expansion protocols that promote a less differentiated phenotype, combined with optimal receptor design and coengineering strategies, along with immunomodulatory therapies that also promote endogenous immunity, offer great promise in surmounting immunometabolic barriers in the TME and curing solid tumors.

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

A long way to the battlefront: CAR T cell therapy against solid cancers.

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

New Chimeric Antigen Receptor Design for Solid Tumors

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Prospects and challenges for use of CAR T cell therapies in solid tumors

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel